D-Cubed Pharma ROI: The $20B Advantage

Commercial Strategy Optimization Oncology & Hematology Cardiovascular Disease Metabolic / Endocrine Disorders Pre-launch Launch Post-launch
Peter Keeling
Founder
Precision Medicine Commercialization
Connect

For years, commentators have criticized pharma for clinging to out-of-date practices. Sales forces, rebate-driven access, and one-size-fits-all launches don't resonate like they used to. Yet the industry already knows the truth about pharma ROI. It's the combined effect of: diagnostics, data, and digital.
When harnessed systematically, these three elements create a competitive leap. Drugs are no longer just sold. They are activated by tests, amplified by data, and accelerated to the right patients with digital engagement.
Leading companies have been piloting these synergies under the umbrella of a precision medicine niche. Now it is time to scale.
Successful pharma ROI comes from strategy. The D-Cubed Model, to be precise. The core of commercialization across all product launches will be to harness diagnostics, data, and digital.

The Evidence Base of Pharma ROI
(As presented in the appendix to the full report)


Over 100 peer-reviewed papers and industry articles prove that biomarker-driven launches succeed faster. The cost is lower, and they deliver higher returns. Real-world adoption studies confirm that embedding diagnostics expands therapy uptake and strengthens payer value. Every pharma board has seen these numbers. The debate is no longer “does precision pay off” - it does - but rather “how to operationalize it portfolio-wide.”
Historically, pharma spent $500M–$1B to launch a drug. More than 70 percent of that gets allocated to legacy tactics such as sales reps, DTC advertising, and congress spend. Less than 5 percent went to diagnostics or patient services. And that's despite diagnostics determining ~70 percent of treatment decisions. The D-Cubed playbook is flipping the economics of pharma ROI.

The Knock-Out Economics of D-Cubed on Pharma ROI
R&D Advantage:

  • Cost per approval: $4.6B (legacy) vs $3.5B (biomarker), ~$1.1B lower with D-Cubed, +27 percent ROI1

  • Time to approval: 10 years (legacy) vs 8 years (biomarker)

  • Probability of success: ~26 percent with biomarker selection vs ~8 percent without2

Launch Advantage:

  • Conversion to treatment: 55 percent (legacy) vs 75 percent (biomarker)3,4

  • Time to peak sales: 7 years vs 5 years 

  • Salesforce and promotion: $160M/year vs $130M/year

  • Patient acquisition cost/start: $22K vs $12K

  • Diagnostic enablement: $0 vs $35M/year

Portfolio advantage - per launch D-Cubed delivers:

  • +$810M NPV uplift (faster uptake, longer tails)5,6,7

  • +$750M saved (shorter pre-launch buildup)5,6,8,9

  • +$300M preserved (slower erosion)

Scaled across portfolios, D-Cubed creates a ~$20B advantage per decade for large pharma.4

The Platformization of D-Cubed Pharma
The strongest D-Cubed pharmas are starting to operate like healthtech companies - platformized, agile, and scalable:

  • Test-triggered activation replaces mass detailing

  • Data flywheel: each test result enriches targeting, pricing, and evidence

  • Pilot to scale in quarters, not years

  • Frictionless pathways from test to treatment

Executed well, D-Cubed is:

  • More valuable - faster uptake, longer revenue tails, higher NPV

  • More agile - reusable infrastructure across portfolios

  • Less vulnerable - defends against patent cliffs and tech disintermediation

Cynic’s Corner (Part 1)

If pharma already knows diagnostics ROI, why hasn’t it shifted faster? The answer is inertia, not ignorance. Pharma is a $1T industry built on a legacy playbook. Turning that supertanker takes more than evidence. It requires a transformation: rewiring budgets, KPIs, and culture.

Yet the shift is happening:

  • Pilots in oncology, rare disease, and immunology

  • Internal pharma ROI models, even if not in investor decks

  • Early D-Cubed experience reallocating budgets toward diagnostics, data, and digital

The real divide is between first movers and late adopters. By the time consensus arrives, D-Cubed leaders will already own the platform advantage.

D-Cubed Proof in Practice: Diagnostics Triggered, Data Led, Digitally Activated Uptake

A leading global pharma company demonstrated the economic power of the D-Cubed model. They combined diagnostics-triggered targeting, real-time lab intelligence, and precision digital engagement to change physician behavior at speed. And helped identify eligible patients who would otherwise be missed.Using DXRX Signal data, machine learning, and NLP, they identified 822 physicians whose testing behavior was suboptimal for a novel biomarker. And instead of relying on traditional sales promotion, they activated a targeted, time-sensitive Physician Engage program. This was sent at the crucial point of diagnostic opportunity.A total of 271 physicians (33%) engaged with the tailored content over the 26-week period. 75 went on to order the biomarker test, with over half of them doing so for the first time, during the initial 4 weeks of engagement.

Across the 26-week campaign, this D-Cubed activation drove 274 tests ordered and identified 81 new therapy-eligible patients. This accelerated access for patients who may never have been tested under legacy models.
This is the economics of D-Cubed in motion. When diagnostics, data, and digital are orchestrated, uptake accelerates, leakage reduces, and value creation begins earlier. The question is no longer whether this works; it does, but how quickly pharma chooses to scale it. Replicated across a portfolio, this model shifts from isolated success to a repeatable platform advantage that compounds over time.
Read article 2 in this series, 'The Competitive Divide' here.

*The economic analysis above is based on an economic meta-analysis of total impact. All citations used in this are linked where relevant above and contained in the reference section available in the final report.

FAQs

What is the D-Cubed Model?
D-Cubed is Diaceutics' framework for maximising pharma ROI by systematically combining three forces: diagnostics, data, and digital. Instead of selling drugs through legacy tactics alone, D-Cubed activates them with tests, amplifies them with real-world data, and accelerates them to the right patients through precision digital engagement.
How does D-Cubed improve pharma ROI?
It flips the economics of a launch. Biomarker-driven approaches lower cost per approval (≈$3.5B vs $4.6B legacy), roughly triple the probability of clinical success (~26% vs ~8%), and lift conversion-to-treatment from 55% to 75%. Scaled across a portfolio, this delivers a ~$20B advantage per decade for large pharma.
Is the evidence behind D-Cubed proven?
Yes. The model is underpinned by over 100 peer-reviewed papers and industry articles, plus real-world adoption studies showing that embedding diagnostics expands therapy uptake and strengthens payer value. The debate has moved on from "does precision pay off" to "how do we operationalise it portfolio-wide."
If the ROI is clear, why hasn't pharma moved faster?
The barrier is inertia, not ignorance. Pharma is a $1T industry built on a legacy playbook, and turning that supertanker means rewiring budgets, KPIs, and culture. The shift is already underway through pilots in oncology, rare disease, and immunology — creating a real divide between first movers and late adopters.
Can you show D-Cubed working in practice?
A leading global pharma used DXRX Signal data, machine learning, and NLP to identify 822 physicians with suboptimal testing behaviour, then activated a targeted Physician Engage programme. Over 26 weeks, 271 physicians (33%) engaged, driving 274 tests ordered and 81 new therapy-eligible patients identified — accelerating access for patients who may otherwise have been missed.
What does it mean to "platformize" D-Cubed pharma?
The strongest players now operate like healthtech companies — agile, scalable, and reusable across portfolios. Test-triggered activation replaces mass detailing, a data flywheel enriches targeting and evidence, and pilots scale in quarters rather than years. The result is a launch engine that is more valuable, more agile, and less vulnerable to patent cliffs.
References

  1. Henderson et al., 2023. Comparative R&D model for precision oncology: ~27% higher ROI and ~$1B lower cost vs non-precision approvals. https://pubmed.ncbi.nlm.nih.gov/37408046/

  2. Wong et al., 2018. Biomarker-stratified trials improve success probability globally. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC/ 
  3. Nadler et al., 2022. Testing rates correlate directly with targeted therapy uptake in NSCLC. https://www.sciencedirect.com  Nimgaonkar et al., 2022. JAMA Oncology - biomarker testing lifts treatment use and outcomes. https://jamanetwork.com 
  4. Diaceutics data on file
  5. Keeling P et al., 2021. Systematic review of cost-effectiveness of diagnostic testing in NSCLC precision medicine. https://www.researchgate.net/publication/352297285_Cost-effectiveness_of_precision_diagnostic_testing_for_precision_medicine_approaches_against_non-small-cell_lung_cancer_A_systematic_review 
  6. Trusheim, Berndt & Douglas, 2007. Stratified medicine economics paper in Nat Rev Drug Discovery. https://pubmed.ncbi.nlm.nih.gov 
  7. Gavan et al., 2018. Economic case for precision medicine with positive Net Monetary Benefit in targeted settings. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC/  
  8. Hu et al., 2019. Enrichment methodological review showing smaller N and faster approvals. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC/ 
  9. ASA, 2016. Statistical enrichment advantages for oncology biomarker trials. http://ww2.amstat.org 
Written By Peter Keeling
Peter Keeling founded Diaceutics in 2005 and has grown it into a global leader in precision medicine commercialization, supporting many of the world's most important biomarker and diagnostic strategies. With more than 33 years of experience as a pharma executive, entrepreneur and strategist, he has been at the forefront of transforming how precision medicine is brought to market, pioneering innovative commercial models across therapeutics, diagnostics and FMCG. A recognised thought leader and published author, Peter is a sought-after speaker on the future of precision medicine and healthcare innovation. He holds degrees from Queen's University Belfast and Buckingham University and was a Visiting Fellow at MIT's Sloan School of Management.
Read more by this author
ABOUT DIACEUTICS

We’ve been with pharma and biotech companies for over 20 years, helping them to make more informed diagnostic and therapeutic decisions based on real-world data. Our platforms and tools provide global insight from a network of laboratories across 50+ countries. 


This unparalleled visibility into real-world testing helps support therapy programs across oncology, cardiology, neurology, autoimmune, rare diseases, and many more. 

Contact us
Commercial Strategy Optimization Oncology & Hematology Cardiovascular Disease Metabolic / Endocrine Disorders Pre-launch Launch Post-launch
Share:

Newsletter sign up

Sign up to our bi-weekly newsletter covering the latest insights to optimize commercialization of diagnostic driven therapies to help empower your decisions.

READY TO DO COMMERCIALIZATION DIFFERENTLY?

Every patient journey contains opportunities to improve testing, engagement, and adoption. We can help you find them so more people get the right therapy sooner.